Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Discharge at day 14, 24mg 62% Improvement Relative Risk Discharge at day 14, 12mg 44% Clinical worsening, 24mg 32% Clinical worsening, 12mg 55% Viral clearance, 24mg, da.. 24% primary Viral clearance, 12mg, da.. 6% Viral clearance, 24mg.. (b) 10% Viral clearance, 12mg.. (b) -3% c19ivm.org Mohan et al. Ivermectin for COVID-19 RCT EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 157 patients in India Improved recovery (p=0.27) and viral clearance (p=0.18), not stat. sig. Mohan et al., J. Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021 Favors ivermectin Favors control
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial
Mohan et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021 (date from earlier preprint)
Mohan et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized,.., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021 (date from earlier preprint)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT in India with low risk patients, comparing 24mg ivermectin, 12mg ivermectin, and placebo showing non-statistically significant improvements in recovery and PCR+ status (day 5 both arms, day 7 24mg only) with treatment, and showing greater improvement for the higher dose arm. Viral load decline was similar in all arms - absolute values are lower for ivermectin in a dose-dependent manner, however the baseline value for the ivermectin groups was lower, leaving less room for change. There were no deaths or use of mechanical ventilation. There were no serious adverse events. Note that our pre-specified protocol prioritizes clinical outcomes over PCR results.
See also: [doyourownresearch.substack.com].
risk of no discharge at day 14, 62.5% lower, RR 0.38, p = 0.27, treatment 2 of 40 (5.0%), control 6 of 45 (13.3%), NNT 12, 24mg.
risk of no discharge at day 14, 43.8% lower, RR 0.56, p = 0.49, treatment 3 of 40 (7.5%), control 6 of 45 (13.3%), NNT 17, 12mg.
risk of clinical worsening, 32.5% lower, RR 0.68, p = 0.72, treatment 3 of 40 (7.5%), control 5 of 45 (11.1%), NNT 28, 24mg.
risk of clinical worsening, 55.0% lower, RR 0.45, p = 0.44, treatment 2 of 40 (5.0%), control 5 of 45 (11.1%), NNT 16, 12mg.
risk of no viral clearance, 23.8% lower, RR 0.76, p = 0.18, treatment 21 of 40 (52.5%), control 31 of 45 (68.9%), NNT 6.1, day 5, 24mg, primary outcome.
risk of no viral clearance, 5.6% lower, RR 0.94, p = 0.82, treatment 26 of 40 (65.0%), control 31 of 45 (68.9%), NNT 26, day 5, 12mg.
risk of no viral clearance, 10.3% lower, RR 0.90, p = 0.65, treatment 20 of 36 (55.6%), control 26 of 42 (61.9%), NNT 16, day 7, 24mg.
risk of no viral clearance, 3.2% higher, RR 1.03, p = 1.00, treatment 23 of 36 (63.9%), control 26 of 42 (61.9%), day 7, 12mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mohan et al., 2 Feb 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 27 authors, average treatment delay 5.0 days, dosage 400μg/kg single dose, 200μg/kg also tested.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Journal Pre-proof Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a singlecentre randomized, placebo-controlled trial Anant Mohan, Pawan Tiwari, Tejas Menon Suri, Saurabh Mittal, Ankit Patel, Avinash Jain, Velpandian Thirumurthy, Ujjalkumar Subhash Das, Tarun Krishna Boppana, Ravindra Mohan Pandey, Sushil Suresh Shelke, Angel Rajan Singh, Sushma Bhatnagar, Shet Masih, Shelly Mahajan, Tanima Dwivedi, Biswajeet Sahoo, Anuja Pandit, Shweta Bhopale, Saurabh Vig, Ritu Gupta, Karan Madan, Vijay Hadda, Nishkarsh Gupta, Rakesh Garg, Ved Prakash Meena, Randeep Guleria PII: S1341-321X(21)00239-7 DOI: https://doi.org/10.1016/j.jiac.2021.08.021 Reference: JIC 1686 To appear in: Journal of Infection and Chemotherapy Received Date: 26 June 2021 Revised Date: 4 August 2021 Accepted Date: 20 August 2021 Please cite this article as: Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Thirumurthy V, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R, Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial, Journal of Infection and Chemotherapy, https://doi.org/10.1016/ j.jiac.2021.08.021. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Title: Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial Authors: Anant Mohana*, Pawan Tiwaria, Tejas Menon Suria, Saurabh Mittala, Ankit Patela, Avinash Jaina, Velpandian Thirumurthyb, Ujjalkumar Subhash Dasb, Tarun Krishna Boppanaa, Ravindra Mohan Pandeyc, Sushil Suresh Shelkea, Angel Rajan Singhd, Sushma Bhatnagare, Shet Masihf, Shelly Mahajanf, Tanima Dwivedig, Biswajeet Sahoog, Anuja Pandite, Shweta Bhopalee, Saurabh Vige, Ritu oo f Guptag, Karan Madana, Vijay Haddaa, Nishkarsh Guptae, Rakesh Garge, Ved Prakash Meenah, re -p r Randeep Guleriaa Author affiliations: a lP Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India Department of Ocular Pharmacology, All India Institute of Medical Sciences, New Delhi, India c Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India d Department of Hospital Administration, All India Institute of Medical Sciences, New Delhi, India e ur na b Jo Department of Onco-Anesthesia, Pain and Palliative Care, All India Institute of Medical Sciences, New Delhi, India f Mahajan Laboratory, New Delhi, India g Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi, India h Department of Medicine, All India Institute of Medical Sciences, New Delhi, India * Correspondence..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit